VIELA BIO

A clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease

Learn More

Our Portfolio

Viela Bio is building a portfolio of innovative biologics that either are first in class or have the potential to be best in class

Our Team

Viela Bio is led by a team of motivated industry experts, aiming to make a difference for inflammation and autoimmunity patients

Our Recent News

Viela Bio Announces Data Presentations at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

| Company General News | No Comments
Gaithersburg, MD—September 9, 2019 – Viela Bio today announced that data from the N-MOmentum trial—the largest global, placebo-controlled study conducted in patients with neuromyelitis optica spectrum disorder (NMOSD)—have been selected…

Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder

| Company General News | No Comments
Gaithersburg, MD—September 6, 2019 –Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).…

Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder

| Company General News | No Comments
Gaithersburg, MD—August 27, 2019 –Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for inebilizumab, an investigational anti-CD19 monoclonal antibody,…

Viela Bio Announces Appointment of Chris Nolet to its Board of Directors

| Company General News | No Comments
Gaithersburg, MD—August 19, 2019 – Viela Bio today announced the appointment of Chris Nolet to its Board of Directors. Mr. Nolet brings more than 38 years of financial leadership experience…